Otonomy, Inc., San Diego, Calif—a biopharmaceutical company focused on the development and commercialization of therapeutics for diseases and disorders of the ear—announced that it will host a Key Opinion Leader meeting on Ménière’s disease at 8:30 a.m. EDT (5:30 a.m. PDT) on June 27, 2017 in New York.
The meeting will feature presentations by opinion leaders Paul R. Lambert, MD, professor and chair, Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, and Anthony A. Mikulec, MD, MBA, professor, chief of otology and neurotology, Saint Louis University School of Medicine, who will discuss the significant disease burden and unmet medical needs in the treatment of Ménière’s disease, review the OTIVIDEX™ Phase 2b clinical trial results, and share their clinical trial experience using OTIVIDEX. Both physicians will be available to answer questions.
In addition, Kathie M. Bishop, PhD, chief scientific officer of Otonomy will provide an updated analysis of the OTIVIDEX Phase 2b results based on the Phase 3 target patient population and review the program timeline.
A live audio webcast of the event and a replay will be available through the Events and Presentations page of the company’s website.